Scynexis Inc is a biotechnology company focused on developing innovative therapies to combat serious infections, particularly those caused by resistant pathogens. The company specializes in researching and advancing novel antifungal treatments aimed at addressing unmet medical needs in infectious diseases. By leveraging its proprietary drug development platform, Scynexis seeks to create transformative solutions that enhance patient outcomes and improve the management of challenging infections in both hospital and outpatient settings. Through its commitment to scientific excellence and rigorous clinical testing, Scynexis strives to make a meaningful impact on public health by providing effective alternatives for patients facing difficult-to-treat infections.